ATOS has 36-month beta value of 1.22. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for ATOS is 125.71M, and currently, short sellers hold a 10.28% ratio of that float. The average trading volume of ATOS on October 24, 2024 was 546.37K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
ATOS) stock’s latest price update
The stock of Atossa Therapeutics Inc (NASDAQ: ATOS) has decreased by -2.16 when compared to last closing price of 1.46. Despite this, the company has experienced a -1.48% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-10-21 that SEATTLE, Oct. 21, 2024 (GLOBE NEWSWIRE) — Atossa Therapeutics, Inc. (NASDAQ: ATOS) (“Atossa” or the “Company”), today announced that Steven Quay, M.D., Ph.D., Chairman and Chief Executive Officer, will join Per Hall, M.D., Professor of Epidemiology at the Department of Medical Epidemiology and Biostatistics at Karolinska Institute, at a fireside chat at BIO-Europe 2024. During the fireside chat, Drs. Quay and Hall will discuss a meaningful approach to combining a state-of-the-art, artificial intelligence (AI)-based risk model with promising emerging therapies that may help prevent breast cancer in high-risk patients. BIO-Europe 2024 is scheduled for November 4-6, 2024, in Stockholm, Sweden. Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
ATOS’s Market Performance
Atossa Therapeutics Inc (ATOS) has seen a -1.48% fall in stock performance for the week, with a 2.77% gain in the past month and a -2.82% plunge in the past quarter. The volatility ratio for the week is 3.07%, and the volatility levels for the past 30 days are at 4.23% for ATOS. The simple moving average for the past 20 days is -1.38% for ATOS’s stock, with a 7.93% simple moving average for the past 200 days.
Analysts’ Opinion of ATOS
Many brokerage firms have already submitted their reports for ATOS stocks, with Maxim Group repeating the rating for ATOS by listing it as a “Buy.” The predicted price for ATOS in the upcoming period, according to Maxim Group is $2 based on the research report published on January 26, 2018 of the previous year 2018.
ATOS Trading at 0.70% from the 50-Day Moving Average
After a stumble in the market that brought ATOS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.16% of loss for the given period.
Volatility was left at 4.23%, however, over the last 30 days, the volatility rate increased by 3.07%, as shares surge +3.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.13% upper at present.
During the last 5 trading sessions, ATOS fell by -0.69%, which changed the moving average for the period of 200-days by +58.03% in comparison to the 20-day moving average, which settled at $1.4490. In addition, Atossa Therapeutics Inc saw 62.33% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATOS starting from Finn Jonathan, who purchase 25,000 shares at the price of $1.77 back on Apr 10 ’24. After this action, Finn Jonathan now owns 25,000 shares of Atossa Therapeutics Inc, valued at $44,250 using the latest closing price.
WEAVER GREGORY L, the Former EVP, CFO, & Director of Atossa Therapeutics Inc, sale 50,000 shares at $0.65 during a trade that took place back on Nov 15 ’23, which means that WEAVER GREGORY L is holding 55 shares at $32,500 based on the most recent closing price.
Stock Fundamentals for ATOS
Current profitability levels for the company are sitting at:
- -1698.44 for the present operating margin
- -0.44 for the gross margin
The net margin for Atossa Therapeutics Inc stands at -1439.44. The total capital return value is set at -0.38. Equity return is now at value -28.00, with -26.68 for asset returns.
Currently, EBITDA for the company is -31.35 million with net debt to EBITDA at 2.61. When we switch over and look at the enterprise to sales, we see a ratio of 5566.47. The receivables turnover for the company is -0.02for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 14.35.
Conclusion
To put it simply, Atossa Therapeutics Inc (ATOS) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
